EPI

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Tuesday, February 27, 2024
Sun Pharma, Collection, MK2, Research, Eli Lilly and Company, ACRS, Atopic dermatitis, Health, Intangibles, Interim, IPR, Therapy, Rheumatoid arthritis, Patient, G&A, Pancreatic cancer, Pharmaceutical industry

Aclaris reported positive results from its Phase 1 MAD trial of ATI-2138 in September 2023.

Key Points: 
  • Aclaris reported positive results from its Phase 1 MAD trial of ATI-2138 in September 2023.
  • Net loss was $1.5 million for the fourth quarter of 2023 compared to $27.6 million for the fourth quarter of 2022.
  • Total revenue was $17.6 million for the fourth quarter of 2023 compared to $7.8 million for the fourth quarter of 2022.
  • Licensing expenses were $5.7 million for the quarter ended December 31, 2023 compared to $0.6 million for the prior year period.

ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study

Retrieved on: 
Monday, February 26, 2024
SAN, Incidence, The Study, AAAAI, Caregiver, Angioedema, Histamine, Principal, ARS, FDA, Quality of life, Anaphylaxis, Body surface area, Data, Convention center, Skin, Safety, Joint task force, Allergy, Patient, Flare, Data analysis, CSU, Erythema, Pediatrics, Asthma, Adrenaline, Itch, American Academy, Pharmaceutical industry

Urticaria is a skin disorder that causes itchy hives and/or angioedema; 50% of chronic urticaria cases1 are non-responsive to first-line antihistamine therapy.

Key Points: 
  • Urticaria is a skin disorder that causes itchy hives and/or angioedema; 50% of chronic urticaria cases1 are non-responsive to first-line antihistamine therapy.
  • “Urticaria is not only a standalone type I allergy disease, but also represents the most frequent symptom observed during type I allergic reactions including anaphylaxis.
  • neffy may provide episodic symptomatic relief of these acute flares or exacerbations to improve the quality of life of urticaria patients.
  • This would follow the anticipated FDA approval of neffy for allergic reactions (Type I) including anaphylaxis in the second half of 2024.

Quarterly System Demo Q1 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 26 March 2024, 09:00 (CET) to 26 March 2024, 13:30 (CET)

Retrieved on: 
Sunday, March 10, 2024
EMA, UI, RPM, NFR, UPD, External, EAF, Location, PMS, Video game

A system demo is an event held at the end of a programme increment (a three-month period of work) to demonstrate the developments achieved in that period and collect stakeholder feedback.

Key Points: 
  • A system demo is an event held at the end of a programme increment (a three-month period of work) to demonstrate the developments achieved in that period and collect stakeholder feedback.
  • Participants have the opportunity to review what has been delivered, give feedback and ask questions on future product increments (planned chunks of work on the final system).
  • Each demo has a dedicated timeslot on the agenda.
  • Live broadcast - 09:00-13:30 Amsterdam time (CET)
    Live broadcast - 09:00-13:30 Amsterdam time (CET)
    Related content
    Related content
    External links
    External links

Unleashing Potential: MakeShift and EPI-USE Partner to Bring Cutting-Edge Employee Scheduling to SAP Clients Worldwide

Retrieved on: 
Friday, March 8, 2024
Cloud, G2, AB, SAP, UX, Health, Growth, Public sector, Attendance, Automation, Workforce, Partnership

This collaboration elevates EPI-USE to the status of a certified delivery partner and reseller, empowering the company to offer MakeShift's award-winning staff scheduling technology to shift-based organizations worldwide.

Key Points: 
  • This collaboration elevates EPI-USE to the status of a certified delivery partner and reseller, empowering the company to offer MakeShift's award-winning staff scheduling technology to shift-based organizations worldwide.
  • Optimized SAP Integration and User Experience: EPI-USE and SAP clients will benefit from streamlined operations, improved scheduling efficiency, and increased productivity through the seamless integration of MakeShift's AI-driven scheduling technology.
  • MakeShift is available on the SAP Store ® and is a part of SAP's Industry Cloud Portfolio.
  • It seamlessly integrates with SAP SuccessFactors® Employee Central, SAP SuccessFactors Employee Central Payroll, and SAP SuccessFactors Time Tracking, while also complementing SAP Time and Attendance Management by Workforce Software.

Olympus Distribution of EndoClot® Showing Steady Adoption in the U.S.

Retrieved on: 
Friday, March 1, 2024
Static pressure, Traction, Blood, Physician, Tropical ulcer, Dissection, SIS, Polyp, Starch, Hemostasis, Artifact, Internationalized domain name, AMP, Inflammation, Adenoma, Safety, ESD, GI, Water, Classification, Perforated ulcer, CO2, PHS, Patient, Bleeding, Trauma, Perforation, Medical imaging

EndoClot products are used by more than 700 accounts, including most of the country's top-ranked (by size) Integrated Delivery Networks (IDNs).

Key Points: 
  • EndoClot products are used by more than 700 accounts, including most of the country's top-ranked (by size) Integrated Delivery Networks (IDNs).
  • Since their launch, EndoClot products have been discussed in close to 20 relevant professional education courses offered via Olympus Continuum, providing physicians with peer-demonstrations of EndoClot technology capabilities during procedures.
  • "Olympus knew that EndoClot technology would be important to improving procedure efficiencies and contributing to improved patient outcomes," said Patrick Romano, Vice President, GI Business Unit Leader, Olympus Corporation of the Americas.
  • A new video highlighting use of the EndoClot PHS and EndoClot SIS has been developed to provide more information: https://www.youtube.com/watch?v=QlCaoiM2Eo0 .

WisdomTree Reports Monthly Metrics for January 2024

Retrieved on: 
Monday, February 12, 2024
Professional Services, Blockchain, Technology, Cryptocurrency, Finance, Asset Management, Digital Cash Management, Digital Assets, DXJ, YTD, AUM, USFR, Gold, Commodity, Commercial property

WisdomTree, Inc. (NYSE: WT), a global financial innovator, today released monthly metrics for January 2024, including assets under management (AUM) and flow data by asset class.

Key Points: 
  • WisdomTree, Inc. (NYSE: WT), a global financial innovator, today released monthly metrics for January 2024, including assets under management (AUM) and flow data by asset class.
  • Robust ~$1 billion of net inflows generated a 21% pace of YTD organic growth across the equity franchise (U.S. + International Developed Markets + Emerging Markets)
    Positive fee impact from strong flows into a mix of high fee funds such as Japan Hedged Equity Fund (DXJ) (0.48% fee rate, +$405 million net inflows), India Earnings Fund (EPI) (0.85% fee rate, +$226 million net inflows) and U.S. Quality Dividend Growth Fund (DGRW) (0.28% fee rate, +$248 million net inflows) outpace outflows in Floating Rate Treasury Fund (USFR) (0.15% fee rate, -$412 million net outflows)
    Outflows in Commodity & Currency category driven primarily by profit taking and de-risking in Oil and Gold products, partially offset by strength in Copper flows
    Expanded WisdomTree Prime™ to 38 states and nearly 70% of the U.S. population

Transphorm at APEC 2024: SuperGaN Innovation for Low to High Power Applications

Retrieved on: 
Tuesday, February 6, 2024
Apps, Applications, Mobile, Wireless, Technology, Security, Software, Networks, Internet, Hardware, Data Management, Artificial Intelligence, Designability, Silicon carbide, Physics, Microchip Technology, Booth, AEC, APEC, Transphorm, Gallium nitride, FIT, Shodan (website), Technical, MOSFET, Silicon, FET, FAE, JEDEC, Electric motor

Silver Partner Transphorm, Inc. (Nasdaq: TGAN)—a global leader in robust GaN power semiconductors—announced today that its APEC 2024 showcase will underscore the company’s continued leadership in broad spectrum (low to high power) GaN power conversion.

Key Points: 
  • Silver Partner Transphorm, Inc. (Nasdaq: TGAN)—a global leader in robust GaN power semiconductors—announced today that its APEC 2024 showcase will underscore the company’s continued leadership in broad spectrum (low to high power) GaN power conversion.
  • This year, Transphorm will highlight major innovation milestones to include the industry’s first 1200 V GaN-on-Sapphire device model and leading short circuit robustness .
  • Reliability: Still leading the industry with a current FIT rate of
  • Transphorm today supports the largest range of power conversion requirements (45 W to 10+ kW) across the widest range of power applications.

VIVUS Provides Update on Pipeline and Program Milestones

Retrieved on: 
Monday, January 8, 2024
Patient, Quality of life, HIV/AIDS, Bloating, Diarrhea, Inflammatory bowel disease, ABPM, Chronic pain, Enzyme replacement therapy, Cystic fibrosis, Heart, Degenerative disease, Exocrine pancreatic insufficiency, Comorbidity, Steatorrhea, Obesity, HIV, Amylase, Orthostatic hypertension, Phentermine, Heart failure, Exercise, Pharmaceutical industry

CAMPBELL, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs, today announced pipeline updates and program milestones.

Key Points: 
  • CAMPBELL, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs, today announced pipeline updates and program milestones.
  • “VIVUS has been continuously dedicated to addressing the therapeutic needs of patients with serious medical conditions and life-limiting diseases, including exocrine pancreatic insufficiency, obesity and pulmonary arterial hypertension,” said John Amos, Chief Executive Officer at VIVUS LLC.
  • QSYMIA® is now the number one branded oral product in the US for obesity treatment.
  • Moreover, VIVUS is actively developing pipeline products focusing on bone marrow transplant preparation (VI-0609) and diabetes treatments (VI-0809 and VI-0810).”

Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108

Retrieved on: 
Wednesday, December 27, 2023
ECO, Doctor of Philosophy, Exocrine pancreatic insufficiency, Medication, MBBS, Patient, Pharmaceutical industry

Under the terms of the agreement, Codexis will receive up to $45M in potential milestone payments, including a $5M upfront payment, as well as single-digit net-sales-based royalties.

Key Points: 
  • Under the terms of the agreement, Codexis will receive up to $45M in potential milestone payments, including a $5M upfront payment, as well as single-digit net-sales-based royalties.
  • Codexis will receive up to an additional $5M if Nestlé Health Science exercises an option to purchase two additional early-stage enzymes being developed for EPI.
  • Nestlé Health Science will be solely responsible for the continued development and commercialization of CDX-7108, including all associated costs.
  • With this asset purchase agreement, Nestlé Health Science may continue advancing the compound through the development process.

First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program

Retrieved on: 
Wednesday, December 27, 2023
IBD, Food, Economics, Diarrhea, FDA, WHO, Exocrine pancreatic insufficiency, COVID, BOCA, Intellectual property, Infection, World Health Organization, First wave, Patient, Inflammatory Bowel Diseases, Ulcerative colitis, Pharmaceutical industry

The non-binding term sheet includes a low seven-figure upfront payment to First Wave BioPharma for rights to Niclosamide, as well as economics related to future milestones and royalties.

Key Points: 
  • The non-binding term sheet includes a low seven-figure upfront payment to First Wave BioPharma for rights to Niclosamide, as well as economics related to future milestones and royalties.
  • Additional details of the transaction will be disclosed upon finalization and execution of the definitive agreement.
  • The drug is a potential non-steroidal anti-inflammatory therapy for the treatment of mild-to-moderate inflammatory bowel diseases (IBD).
  • Intellectual property for niclosamide formulations governing composition of matter and methods of use extends beyond 2040.